[HTML][HTML] Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly …
GE Konecny, AEW Hendrickson, TM Davidson… - Gynecologic …, 2021 - Elsevier
Purpose Insulin-like growth factor (IGF) signaling is implicated in pathogenesis and
chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy and …
chemotherapy resistance of epithelial ovarian cancer (EOC). We explored efficacy and …
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 …
I Ray-Coquard, P Haluska, S O'Reilly, PH Cottu, L Elit… - 2013 - ascopubs.org
5515 Background: IGF signaling has been implicated in the pathogenesis and progression
of ovarian cancer (OC). Single agent activity and safety of ganitumab (AMG 479), a fully …
of ovarian cancer (OC). Single agent activity and safety of ganitumab (AMG 479), a fully …
Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer
TM Davidson, CL Lebreton, AEW Hendricksen… - Gynecologic …, 2023 - Elsevier
Background IGF signaling has been implicated in the pathogenesis and progression of
ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a fully …
ovarian carcinoma (OC). Single agent activity and safety of ganitumab (AMG 479), a fully …
A phase II, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with carboplatin/paclitaxel as front-line therapy for …
GE Konecny, P Haluska, F Janicke, J Sehouli… - 2014 - ascopubs.org
5529 Background: IGF signaling has been implicated in the pathogenesis and progression
of ovarian cancer (OC). Ganitumab (GAN; AMG 479) is an investigational, fully human …
of ovarian cancer (OC). Ganitumab (GAN; AMG 479) is an investigational, fully human …
Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study
G Daniele, F Raspagliesi, G Scambia… - International Journal of …, 2021 - ijgc.bmj.com
Objective To explore the clinical and biological prognostic factors for advanced ovarian
cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab …
cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab …
Ganitumab (AMG 479) inhibits IGF-II–dependent ovarian cancer growth and potentiates platinum-based chemotherapy
PJ Beltran, FJ Calzone, P Mitchell, YA Chung… - Clinical Cancer …, 2014 - AACR
Purpose: Insulin-like growth factor 1 receptor (IGF-IR) has been implicated in the
pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal …
pathogenesis of ovarian cancer. Ganitumab is an investigational, fully human monoclonal …
Final results from GCIG/ENGOT/AGO‐OVAR 12, a randomised placebo‐controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed …
I Ray‐Coquard, D Cibula, MR Mirza… - … journal of cancer, 2020 - Wiley Online Library
AGO‐OVAR 12 investigated the effect of adding the oral triple angiokinase inhibitor
nintedanib to standard front‐line chemotherapy for advanced ovarian cancer. At the primary …
nintedanib to standard front‐line chemotherapy for advanced ovarian cancer. At the primary …
Improving first-line therapy of advanced ovarian cancer–the AGO Ovarian Cancer Study Group perspective
A Du Bois, J Pfisterer, W Meier… - International Journal of …, 2003 - ijgc.bmj.com
This review displays the AGO Ovarian Cancer Study Group approach towards evaluation of
improvement options in first-line therapy of advanced ovarian cancer. Prospectively …
improvement options in first-line therapy of advanced ovarian cancer. Prospectively …
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB–IV
W Meier, A du Bois, J Rau, M Gropp-Meier… - Gynecologic …, 2012 - Elsevier
OBJECTIVES: This study evaluates whether a molecular targeted therapy with the
farnesyltransferase inhibitor lonafarnib added to standard chemotherapy in first-line …
farnesyltransferase inhibitor lonafarnib added to standard chemotherapy in first-line …
Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: a phase II, open label, randomized, controlled trial
Background Treatment of patients with platinum resistant/refractory epithelial ovarian cancer
(EOC) is an unmet need. We evaluated the role of oral metronomic therapy in this setting …
(EOC) is an unmet need. We evaluated the role of oral metronomic therapy in this setting …